V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160016045 | 160016273 | 1.58 | 109 | Palliative (P) | 2018-10-28 | 2018-11-14 | EW Rel rEECur Irinotecan/Temozolomide | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 100837130 |
| 160016053 | 160016274 | 0 | 97 | Palliative (P) | 2013-06-11 | 2017-02-26 | GEMCITABINE | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100007149 |
| 160016054 | 160016275 | 1.79 | 74.6 | null | 2019-09-20 | 2019-10-01 | PEMBROLIZUMAB | 02 | null | ETOP 13-18 BEAT-MESO TRIAL | 101490712 |
| 160016059 | 160016276 | 1.6 | null | Curative (C) | 2017-02-09 | 2017-03-03 | Ifosfamide | N | N | DABRAFENIB + TRAMETINIB | 101423964 |
| 160016071 | 160016277 | 1.69 | 55.3 | Curative (C) | 2019-06-19 | 2019-11-07 | Temozolomide 200mg/m2 | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101610285 |
| 160016079 | 160016278 | 1.57 | 92 | Curative (C) | 2017-07-03 | 2017-07-19 | Trial Unspecified | 02 | N | DACTINOMYCIN + CYCLO + VINCRISTINE | 101778619 |
| 160016100 | 160016279 | 1.95 | 15.4 | null | 2021-03-07 | 2021-03-08 | Etoposide + Ifosfamide (5 days) | 02 | null | VINCRISTINE | 100759151 |
| 160016102 | 160016280 | 1.54 | 96.3 | null | 2018-11-16 | 2019-06-20 | EW Rel rEECur Topotecan/Cyclophosphamide | 02 | null | RMS 2005 TRIAL | 100224260 |
| 160016121 | 160016283 | 0 | 104 | Curative (C) | 2018-01-18 | 2018-09-08 | IRINOTECAN + TEMOZOLOMIDE + VINCRISTINE | 02 | N | NOT MATCHED | 100093224 |
| 160016122 | 160016284 | 0 | 60 | Palliative (P) | 2018-11-20 | 2019-06-04 | Etoposide + Ifosfamide (5 days) | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100365512 |
| 160016124 | 160016285 | null | 82 | null | 2018-09-19 | 2018-11-06 | IVADo | 02 | null | DOXORUBICIN + IFOSFAMIDE | 101007495 |
| 160016126 | 160016286 | 1.64 | 73.8 | Curative (C) | 2019-12-18 | 2019-12-18 | EURO-EWING | N | N | EW EUROEWING 2012 ARM B VC | 100019798 |
| 160016128 | 160016287 | 1.15 | 45 | Neo-adjuvant (N) | 2020-06-13 | 2020-06-20 | null | 2 | N | CYCLOPHOSPHAMIDE + VINORELBINE | 101536348 |
| 160016143 | 160016288 | 1.62 | 99 | null | 2018-01-10 | 2018-01-13 | Doxorubicin + Ifosfamide | 02 | null | IVA | 101844682 |
| 160016154 | 160016289 | 1.64 | 57 | Curative (C) | 2017-12-25 | 2018-10-08 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | DACARBAZINE + DOXORUBICIN | 100806339 |
| 160016155 | 160016290 | 1.74 | 49.6 | 03 | 2020-10-02 | 2020-10-08 | Doxorubicin + Ifosfamide | 02 | N | STS RHABDO RMS 2005 VIN CYCLO | 100008589 |
| 160016159 | 160016291 | 1.85 | 48.1 | Palliative (P) | 2017-03-16 | 2017-03-16 | ATEZOLIZUMAB + BEVACIZUMAB | 02 | N | EW EUROEWING 2012 ARM A VAC | 100202740 |
| 160016166 | 160016292 | 1.5 | 85.1 | Palliative (P) | 2019-01-15 | 2019-01-24 | Pemetrexed | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100421690 |
| 160016170 | 160016293 | 1.55 | 184 | Neo-adjuvant (N) | 2020-04-22 | 2020-05-19 | Trial Unspecified | 02 | N | PEMBROLIZUMAB | 100415905 |
| 160016172 | 160016294 | 1.74 | 76.05 | Palliative (P) | 2016-08-28 | 2016-09-04 | Irinotecan + Temozolomide | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101857592 |
| 160016178 | 160016295 | 1.79 | 86.2 | null | 2017-10-13 | 2018-09-23 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | null | CISPLATIN + CAPECITABINE + EPIRUBICIN | 100892173 |
| 160016183 | 160016296 | 1.85 | 98 | Curative (C) | 2017-12-19 | 2017-12-19 | EW EuroEwing 2012 Arm B VC | 02 | null | CISPLATIN + ETOPOSIDE | 100705666 |
| 160016189 | 160016297 | 0 | 66.4 | Palliative (P) | 2017-06-18 | 2017-07-19 | STS Non-Rhabdo EpSSG 2005 Ifos | 02 | N | TRIAL | 100636353 |
| 160016192 | 160016298 | 1.73 | 101.4 | Palliative (P) | 2021-04-14 | 2021-04-17 | Rucaparib | 02 | N | IVA | 100466954 |
| 160016198 | 160016299 | 0 | 114.6 | Curative (C) | 2017-10-29 | 2017-11-27 | NB HRNBL-1 TVD | Y | N | IFOSFAMIDE | 100051458 |
| 160016202 | 160016300 | 1.59 | 83 | Palliative (P) | 2020-04-10 | 2020-04-13 | CYCLO + DOXORUBICIN + VINCRISTINE | 02 | N | IFOSFAMIDE | 100245376 |
| 160016208 | 160016301 | 1.77 | 91 | null | 2017-03-07 | 2017-04-15 | Niraparib | 02 | null | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 101453452 |
| 160016209 | 160016302 | 1.59 | 17.4 | Curative (C) | 2021-02-11 | 2021-03-03 | Doxorubicin + Ifosfamide | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100261378 |
| 160016212 | 160016303 | 0 | 94.4 | Adjuvant (A) | 2020-10-02 | 2020-10-17 | CEDIRANIB | 02 | N | CNS LGG TEMOZOLOMIDE | 100469851 |
| 160016214 | 160016304 | 1.23 | 62.1 | Adjuvant (A) | 2018-05-31 | 2018-07-21 | ETOPOSIDE | 02 | N | TRIAL | 100377752 |
| 160016215 | 160016305 | 0 | 73 | 03 | 2017-05-03 | 2018-06-30 | Ifosfamide | 01 | N | IPM | 101711099 |
| 160016216 | 160016306 | 1.7 | 73.4 | Palliative (P) | 2020-01-14 | 2020-01-21 | Methotrexate + Vinblastine | 02 | N | EW EUROEWING 2012 ARM B VDC | 100889867 |
| 160016227 | 160016307 | 1.81 | 49 | null | 2017-08-27 | 2018-11-16 | IVA | 02 | null | NB RELAPSED CCLG GUIDELINES TVD | 100301185 |
| 160016234 | 160016308 | 1.82 | 34.1 | Palliative (P) | 2018-08-08 | 2018-09-30 | STS Rhabdo VIT0910 Vinc Irino Temoz | 02 | N | DACARBAZINE | 101787831 |
| 160016241 | 160016309 | 0 | 21.2 | Palliative (P) | 2019-04-03 | 2019-04-11 | Dacarbazine | N | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101610471 |
| 160016251 | 160016310 | 1.73 | 63 | null | 2020-02-17 | 2020-03-04 | Olaparib | null | null | OST M | 100455664 |
| 160016264 | 160016311 | 0 | 106 | null | 2016-06-22 | 2016-11-21 | PEMBROLIZUMAB | 02 | null | GEMCITABINE | 100463884 |
| 160016268 | 160016312 | 1.62 | 82.2 | Palliative (P) | 2020-10-23 | 2020-10-27 | EW EuroEwing 2012 Arm B IE | 02 | N | TRIAL | 101200519 |
| 160016271 | 160016313 | 1.58 | 43.5 | null | 2022-03-11 | 2022-04-12 | Dacarbazine | 99 | null | CARBOPLATIN + LIPOSOMAL DOX | 100297163 |
| 160016279 | 160016314 | 1.57 | 140 | Curative (C) | 2017-05-10 | 2019-05-08 | Cyclophosphamide + Topotecan | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVAVV | 100874490 |
| 160016280 | 160016315 | 1.93 | 81.6 | Neo-adjuvant (N) | null | null | GEMCITABINE | 02 | N | STS RHABDO VIT0910 VINC IRINO TEMOZ | 101433050 |
| 160016283 | 160016316 | 1.74 | 79 | null | 2018-12-07 | 2019-02-08 | EW EuroEwing 2012 Arm B VDC | null | null | GEMCITABINE | 101060221 |
| 160016287 | 160016317 | 1.67 | 57.6 | Palliative (P) | 2018-07-25 | 2018-08-13 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | null | TRIAL | 101210219 |
| 160016301 | 160016319 | 1.77 | 15.6 | 03 | 2016-11-15 | 2016-12-06 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | N | STS RHABDO RMS 2005 VIN CYCLO | 100811274 |
| 160016304 | 160016320 | 1.78 | 40.4 | Neo-adjuvant (N) | 2018-05-02 | 2018-05-03 | Cyclophosphamide oral | 01 | N | FLAG + IDARUBICIN | 100017071 |
| 160016307 | 160016321 | 1.57 | 61.5 | null | null | 2017-10-23 | EW Rel rEECur Gemcitabine/Docetaxel | 02 | null | DOXORUBICIN + IFOSFAMIDE | 100095618 |
| 160016308 | 160016322 | 1.59 | 54 | null | 2017-10-29 | 2019-06-09 | STS Rhabdomyosarcoma RMS 2005 IVADo | 02 | null | NIRAPARIB | 101681747 |
| 160016309 | 160016323 | 1.61 | 85 | 03 | 2017-10-07 | 2017-10-08 | IVADo | 01 | N | EW EUROEWING 2012 ARM B IE | 100318550 |
| 160016314 | 160016324 | 1.14 | 32.8 | Palliative (P) | 2016-06-13 | 2016-06-27 | NB HRNBL-1 Isotretinoin | 02 | null | TRIAL | 100726127 |
| 160016316 | 160016325 | 1.66 | 21.8 | null | 2017-04-28 | 2017-07-02 | PEMBROLIZUMAB | 02 | null | NOT MATCHED | 100605956 |